Quality of Life and Drug Abuse

  • S. Assari
  • M. Jafari
Reference work entry


In the absence of treatment, quality of life (QOL) decreases as substance use progresses, but appropriate treatment has proved to improve QOL of substance users. In this regard, several substances have been studied and several questionnaires have been used. Some studies have tried to explain the causes of QOL decrease in substance users. It seems that QOL in substance use is not explained as enough as other somatic and psychiatric conditions. There is a lack of data in this field especially regarding the QOL of substance users from developing countries with different pattern of use. In developing countries, adolescents’ and elderly groups’ Specific QOL measures for substance use are less designed. It is not clear whether QOL of the substance users is associated with poor outcomes such as mortality. Our knowledge is also little regarding the association between the level of  drug dependency and severity of substance use with QOL. Moderators, mediators and coping are less studied. QOL is not comprehensively studied in different levels of drug-taking including  drug use, misuse and dependency ( drug addiction), which have various definitions, and may have different impacts on QOL. Associated variables of QOL and also prediction models are less presented. Substance use, misuse and dependency specific questionnaires are topics which are needed in future research.


Drug User Methadone Maintenance Treatment Mental Component Summary Score Substance User Shared Syringe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


human immunodeficiency virus


injecting drug users


injection drug users


injection drug user quality of life scale


mental component score


 methadone maintenance-therapy


opiate treatment index


physical component score


perceived social support scale


quality of life


quality of well-being scale


short form 36


satisfaction with life scale


  1. Addington-Ha UJ, Kalra L. (2001). BMJ. 322: 1417–1420.CrossRefGoogle Scholar
  2. Arday DR, Milton MH, Husten CG, Haffer SC, Wheeless SC, Jones SM, Johnson RE. (2003). Am J Prev Med. 24: 234–241.PubMedCrossRefGoogle Scholar
  3. Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martín-Santos R, Torrens M. (2008). Subst Use Misuse. 43(5): 612–632.PubMedCrossRefGoogle Scholar
  4. Baker F, Intagliata J. (1982). Eval Program Plann. 5: 69–79.PubMedCrossRefGoogle Scholar
  5. Bell M, Greig T, Gill P, Whelahan H, Bryson G. (2002). Psychiatr Serv. 53: 63–69.PubMedCrossRefGoogle Scholar
  6. Brogly S, Mercier C, Bruneau J, Palepu A, Franco E. (2003). Substance Use Misuse. 38: 965–992.PubMedCrossRefGoogle Scholar
  7. Carretero MD, Burgess AP, Soler P, Soler M, Catalan J. (1996). AIDS. 10: 1699–1705.PubMedGoogle Scholar
  8. Daeppen JB, Krieg MA, Burnand B, Yersin B. (1998). Am J Drug Alcohol Abuse. 24: 685–694.PubMedCrossRefGoogle Scholar
  9. Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. (2004). Hepatology. 39: 74–80.PubMedCrossRefGoogle Scholar
  10. Darke S, Hall W, Wodak A, Heather N, Ward J. (1992). Br J Addict. 87: 733–742.PubMedCrossRefGoogle Scholar
  11. Darke S, Ward J, Hall W, Heather N, Wodak A. (1991). The Opiate Treatment Index (OTI) Researcher’s Manual. Report. National Drug & Alcohol Research Centre, Sydney.Google Scholar
  12. Falck RS, Wang J, Carlson RG, Siegal HA: 2000, Crack-cocaine use and mental health status as defined by the SF-36. Addictive Behaviors 25:579–584.PubMedCrossRefGoogle Scholar
  13. Hubley AM, Russell LB, Palepu A. (2005). Health Qual Life Outcomes. 3: 43.PubMedCrossRefGoogle Scholar
  14. Kertesz SG, Larson MJ, Horton NJ, Winter M, Saitz R, Samet JH. (2005). Med Care. 43(6): 574–585.PubMedCrossRefGoogle Scholar
  15. Koch T. (2000). Soc Sci Med. 51: 419–427.PubMedCrossRefGoogle Scholar
  16. Kraemer KL, Maisto SA, Conigliaro J, McNeil M, Gordon AJ, Kelley ME. (2002). J Gen Intern Med. 17: 382–386.PubMedGoogle Scholar
  17. Margolese HC, Carlos Negrete J, Tempier R, Gill K. (2006). Schizophr Res. 83(1): 65–75.PubMedCrossRefGoogle Scholar
  18. McKenna M, Chick J, Buxton M, Howlett H, Patience D, Ritson B. (1996). Alcohol Alcohol. 31: 565–576.PubMedGoogle Scholar
  19. Mendlowicz MV, Stein MB. (2000). Am J Psychiatr.157(5): 669–682.PubMedCrossRefGoogle Scholar
  20. Metzger DS, O’Brien CP. (1990). Substance abuse: the challenge of assessment. In: Spilker B (ed.) Quality of Life Assessments in Clinical Trials. Raven Press, Ltd., New York, pp. 237–246.Google Scholar
  21. Neuner B, Miller PM, Felsmann B, Weiss-Gerlach E, Neumann T, Wernecke KD, Spies C. (2005). Health Qual Life Outcomes. 3: 77.PubMedCrossRefGoogle Scholar
  22. Padaiga Z, Subata E, Vanagas G. (2007). Medicina (Kaunas). 43(3): 235–41.Google Scholar
  23. Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Heyward W, Francis D. (2007). J Med Assoc Thai. 90(11): 2442–2448.PubMedGoogle Scholar
  24. Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvaros J, Castillo C, Magri N, Martin S, Vazquez JM. (2004). Substance Use Misuse. 39: 1353–1368.PubMedCrossRefGoogle Scholar
  25. Reid A, Lynskey M, Copeland J. (2000). Aust N Z J Public Health. 24: 596–602.PubMedCrossRefGoogle Scholar
  26. Richter D, Eikelmann B, Berger K. (2004). Qual Life Res. 13: 907–914.PubMedCrossRefGoogle Scholar
  27. Russell LB, Hubley AM, Palepu A, Zumbo BD. (2003). J Psychoactive Drugs. 35(4): 497–502.Google Scholar
  28. Maremmani I, Pani PP, Pacini M, Perugi G. (2007). J Subst Abuse Treat. 33(1): 91–98.PubMedCrossRefGoogle Scholar
  29. Reynolds GL, Fisher DG, Klahn JA, Wood MM. (2003). J Psychoactive Drugs. 35(4): 497–502.PubMedGoogle Scholar
  30. Russell LB, Hubley AM. (2005). Int J Testing. 5: 105–131.CrossRefGoogle Scholar
  31. Ryan CF, White JM. (1996). Addiction. 91: 39–45.PubMedCrossRefGoogle Scholar
  32. Stein MD, Mulvey KP, Plough A, Samet JH. (1998). J Subst Abuse. 10: 75–84.PubMedCrossRefGoogle Scholar
  33. Stoermer R, Drewe J, Dursteler-Mac Farland KM, Hock C, Mueller-Spahn F, Ladewig D. et al. (2003). Biol Psychiatry. 54(8): 854–861.PubMedCrossRefGoogle Scholar
  34. te Vaarwerk MJ, Gaal EA. (2001). Eur J Public Health. 11(1): 109–115.PubMedCrossRefGoogle Scholar
  35. Torrens M, San L, Martinez A, Castillo C, Domingo-Salvany A, Alonso J. (1997). Addiction. 92: 707–716.PubMedCrossRefGoogle Scholar
  36. Volk RJ, Cantor SB, Steinbauer JR, Cass AR. (1997). Alcohol Clin Exp Res. 21: 899–905.PubMedCrossRefGoogle Scholar
  37. Williamson S, Gossop M, Powis B, Griffiths P, Fountain J, Strang J. (1997). Drug Alcohol Depend. 44(2–3): 87–94.PubMedCrossRefGoogle Scholar
  38. Wilson D, Parsons J, Wakefield M. (1999). Prev Med. 29: 139–144.PubMedCrossRefGoogle Scholar
  39. Zhang B, Yang J, Luan R, Zhang Y. et al. (2007). Wei Sheng Yan Jiu. 36(5): 591–595.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • S. Assari
    • 1
  • M. Jafari
    • 1
  1. 1.Department of studies in AddictionMedicine and Health Promotion InstituteTehranIran

Personalised recommendations